Expert Perspectives on Fixed Duration Therapy with Venetoclax + Obinutuzumab

January 18, 2024

By Sameer A. Parikh, MD
Sikander Ailawadhi, MD

Opinion

Video

A panel of experts discuss the role of fixed duration therapy with venetoclax and obinutuzumab, outlining their general approach for patient selection.

EP: 1.Evolving Front-line Treatment Options for CLL

EP: 2.Navigating 1L Treatment Selection with BTKis in CLL

EP: 3.Updates on BTKi Monotherapy for CLL in the Frontline Setting

EP: 4.The Role of BTKi + Obinutuzumab for 1L Treatment of CLL

Now Viewing

EP: 5.Expert Perspectives on Fixed Duration Therapy with Venetoclax + Obinutuzumab

EP: 6.Updates on Combination Treatment Approaches with BTKi + Venetoclax

EP: 7.Navigating Treatment Selection for CLL in the Relapsed/Refractory Setting

EP: 8.Expert Insights on Extended Follow-Up Data from ALPINE and ELEVATE-RR

EP: 9.Consideration Factors in Treatment Selection for BTKi Therapy in R/R CLL

EP: 10.Key Considerations in Managing Hypertension Risk with BTKis in CLL

EP: 11.Expert Perspectives on Managing Risk of Atrial Fibrillation with BTKis in CLL

EP: 12.Managing Bleeding Risk in Patients with CLL on BTKi Therapy

EP: 13.Utilizing Real-World Data for Informed Decision-Making in CLL

EP: 14.Navigating Treatment Resistance and Sequencing in CLL

EP: 15.Advancements with Novel Treatment Approaches in CLL

EP: 16.Future Perspectives and Unmet Needs in CLL

Stay up to date on recent advances in the multidisciplinary approach to cancer.

Subscribe Now!